Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries

Molecular Medicine

Volumn 17, Issue 5-6, 2011, Pages 448-456

  Shein, Na'ama A ^a   Shohami, Esther ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIMETHYLAMINO N [5 (2 MERCAPTOACETYLAMINO)PENTYL]BENZAMIDE; 4 PHENYLBUTYRIC ACID; BUTYRIC ACID; CASPASE 3; GIVINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ARTICLE; BIOACCUMULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INJURY; COGNITION; DEACETYLATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FUNCTIONAL STATUS; GLIA CELL; HISTONE ACETYLATION; HOMEOSTASIS; HUMAN; INFLAMMATION; NERVE DEGENERATION; NERVOUS SYSTEM INJURY; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TISSUE INJURY; TRANSCRIPTION REGULATION; TRAUMATIC BRAIN INJURY; TREATMENT DURATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; TRAUMA, NERVOUS SYSTEM;

EID: 79957939679     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00038     Document Type: Article

References (91)

1. Gallen CC. (2004) Strategic challenges in neu-rotherapeutic pharmaceutical development. NeuroRx. 1:165-180.
2. Leker RR, Shohami E, Constantini S. (2002) Experimental models of head trauma. Acta Neu-rochir. Suppl. 83:49-54.
3. Lipinski C, Hopkins A. (2004) Navigating chemical space for biology and medicine. Nature. 432:855-861.
4. Morganti-Kossmann MC, Yan E, Bye N. (2010) Animal models of traumatic brain injury: is there an optimal model to reproduce human brain injury in the laboratory? Injury. 41 Suppl 1:S10-S13.
5. Bramlett HM, Dietrich WD. (2004) Pathophysiol-ogy of cerebral ischemia and brain trauma: similarities and differences. J. Cereb. Blood Flow Metab. 24:133-150.
6. Candelario-Jalil E. (2009) Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. Curr. Opin. Investig. Drugs 10:644-654.
7. Benowitz LI, Carmichael ST. (2010) Promoting axonal rewiring to improve outcome after stroke. Neurobiol. Dis. 37:259-266.
8. De F P, Fellus J, Polito MZ, Thompson JW, Moser RS, DeLuca J. (2009) The new neuroscience frontier: promoting neuroplasticity and brain repair in traumatic brain injury. Clin. Neuropsychol. 23:1391-1399.
9. Pape TL, Rosenow J, Lewis G. (2006) Transcranial magnetic stimulation: a possible treatment for TBI. J. Head Trauma Rehabil. 21:437-451.
10. Hahnen E, Hauke J, Trankle C, Eyupoglu IY, Wirth B, Blumcke I. (2008) Histone deacetylase inhibitors: possible implications for neurodegen-erative disorders. Expert Opin. Investig. Drugs. 17:169-184.
11. Jin K, Mao XO, Simon RP, Greenberg DA. (2001) Cyclic AMP response element binding protein (CREB) and CREB binding protein (CBP) in global cerebral ischemia. J. Mol. Neurosci. 16:49-56.
12. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, Boutillier AL. (2003) Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 22:6537-49.
13. Camelo S, et al. (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune en-cephalomyelitis. J. Neuroimmunol. 164:10-21.
14. Gardian G, et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280:556-563.
15. Ryu H, et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93:1087-1098.
16. Thomas EA, et al. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcrip-tional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 105:15564-1559.
17. Jenuwein T, Allis CD. (2001) Translating the histone code. Science. 293:1074-1080.
18. Saha RN, Pahan K. (2006) HATs and HDACs in neurodegeneration: a tale of disconcerted acety-lation homeostasis. Cell Death Differ. 13:539-350.
19. Kouzarides T. (2007) Chromatin modifications and their function. Cell. 128:693-705.
20. Kruhlak MJ, et al. (2001) Regulation of global acetylation in mitosis through loss of histone acetyltransferases and deacetylases from chro-matin. J. Biol. Chem. 276:38307-38319.
21. Glozak MA, Sengupta N, Zhang X, Seto E. (2005) Acetylation and deacetylation of non-histone proteins. Gene. 363:15-23.
22. Hubbert C, et al. (2002) HDAC6 is a microtubule-associated deacetylase. Nature. 417:455-458.
23. Michan S, Sinclair D. (2007) Sirtuins in mammals: insights into their biological function. Biochem. J. 404:1-13.
24. Zhang Y, et al. (2003) HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22:1168-1179.
25. Kazantsev AG, Thompson LM. (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7:854-868.
26. Hildmann C, Riester D, Schwienhorst A. (2007) Histone deacetylases: an important class of cellular regulators with a variety of functions. Appl. Microbiol. Biotechnol. 75:487-497.
27. Wen YD, et al. (2000) The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. U. S. A. 97:7202-7207.
28. Yang WM, Tsai SC, Wen YD, Fejer G, Seto E. (2002) Functional domains of histone deacetyl -ase-3. J. Biol. Chem. 277:9447-9454.
29. Blander G, Guarente L. (2004) The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73:417-435.
30. Gao L, Cueto MA, Asselbergs F, Atadja P. (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277:25748-25755.
31. Boutillier AL, Trinh E, Loeffler J P. (2003) Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J. Neurochem. 84:814-828.
32. Steffan JS, et al. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 97:6763-6768.
33. Hockly E, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100:2041-2046.
34. Avila AM, et al. (2007) Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117:659-671.
35. Kilgore M, et al. (2010) Inhibitors of class 1 his-tone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 35:870-880.
36. Langley B, Gensert JM, Beal MF, Ratan RR. (2005) Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuro-protective agents. Curr. Drug Targets CNS Neurol. Disord. 4:41-50.
37. Lye TC, Shores EA. (2000) Traumatic brain injury as a risk factor for Alzheimer's disease: a review. Neuropsychol. Rev. 10:115-129.
38. Roberts GW, et al. (1994) Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 57:419-425.
39. Atweh GF, et al. (1999) Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 93:1790-1797.
40. Gerstner T, Bell N, Konig S. (2008) Oral valproic acid for epilepsy: long-term experience in therapy and side effects. Expert Opin. Pharmacother. 9:285-292.
41. Khan O, La Thangue NB. (2008) Drug insight: hi-stone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat. Clin. Pract. Oncol. 5:714-726.
42. Langley B, Brochier C, Rivieccio MA. (2009) Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke. 40:2899-2905.
43. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuropro-tective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321:892-901.
44. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89:1358-1367.
45. Langley B, et al. (2008) Pulse inhibition of histone deacetylases induces complete resistance to ox-idative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21 (waf1/cip1) in cell cycle-independent neuro -protection. J. Neurosci. 28:163-176.
46. Qi X, Hosoi T, Okuma Y, Kaneko M, Nomura Y. (2004) Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 66:899-908.
47. Kim HJ, Leeds P, Chuang DM. (2009) The HDAC inhibitor, sodium butyrate, stimulates neurogen-esis in the ischemic brain. J. Neurochem. 110:1226-1140.
48. Endres M, et al. (2000) DNA methyltransferase contributes to delayed ischemic brain injury. J. Neurosci. 20:3175-3181.
49. Faraco G, et al. (2006) Pharmacological inhibition of histone deacetylases by suberoylanilide hy-droxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 70:1876-1884.
50. Yildirim F, et al. (2008) Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp. Neurol. 210:531-542.
51. Bolden JE, Peart MJ, Johnstone RW. (2006) Anti-cancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5:769-784.
52. Khan N, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409:581-589.
53. Shein NA, et al. (2009) Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 23:4266-4275.
54. Dinarello CA. (2010) Anti-inflammatory agents: present and future. Cell. 140:935-950.
55. Emsley HC, Tyrrell PJ. (2002) Inflammation and infection in clinical stroke. J. Cereb. Blood Flow Metab. 22:1399-1419.
56. Shohami E, Ginis I, Hallenbeck JM. (1999) Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev. 10:119-130.
57. Aronowski J, Hall CE. (2005) New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurol. Res. 27:268-279.
58. Sinn DI, et al. (2007) Valproic acid-mediated neu-roprotection in intracerebral hemorrhage via his-tone deacetylase inhibition and transcriptional activation. Neurobiol. Dis. 26:464-472.
59. Beauchamp K, Mutlak H, Smith WR, Shohami E, Stahel PF. (2008) Pharmacology of traumatic brain injury: where is the "golden bullet"? Mol. Med. 14:731-740.
60. Zhang B, et al. (2008) HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res. 1226:181-191.
61. Moppett IK. (2007) Traumatic brain injury: assessment, resuscitation and early management. Br. J. Anaesth. 99:18-31.
62. Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452-1458.
63. Grosjean MB, et al. (2007) Immunohistochemical characterization of Fas (CD95) and Fas Ligand (FasL/CD95L) expression in the injured brain: relationship with neuronal cell death and inflammatory mediators. Histol. Histopathol. 22:235-250.
64. Yatsiv I, et al. (2005) Erythropoietin is neuropro-tective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 19:1701-1703.
65. Marinova Z, et al. (2009) Valproic acid induces functional heat-shock protein 70 via class I his-tone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J. Neurochem. 111:976-987.
66. Huuskonen J, Suuronen T, Nuutinen T, Kyrylenko S, Salminen A. (2004) Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br. J. Pharmacol. 141:874-880.
67. Glauben R, et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176:5015-5022.
68. Glauben R, et al. (2008) Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 57:613-622.
69. Armeanu S, et al. (2005) Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J. Hepatol. 42:210-217.
70. Barbetti V, et al. (2008) Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene. 27:1767-1778.
71. Carlisi D, et al. (2008) Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int. J. Oncol. 32:177-184.
72. Dash PK, et al. (2010) Valproate administered after traumatic brain injury provides neuropro-tection and improves cognitive function in rats. PLoS One. 5:e11383.
73. Dash PK, Orsi SA, Moore AN. (2009) Histone deactylase inhibition combined with behavioral therapy enhances learning and memory following traumatic brain injury. Neuroscience. 163:1-8.
74. Gaub P, et al. (2010) HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/CAF- dependent p53 acetylation. Cell Death Differ. 17:1392-1408.
75. Levenson JM, Sweatt JD. (2005) Epigenetic mechanisms in memory formation. Nat. Rev. Neurosci. 6:108-118.
76. Vecsey CG, et al. (2007) Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci. 27:6128-6140.
77. Biermann J, et al. (2010) Valproic acid-mediated neu-roprotection and regeneration in injured retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 51:526-534.
78. Matalon S, et al. (2010) The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and mono-cytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 54:1-9.
79. Kozikowski A P, et al. (2007) Functional differences in epigenetic modulators: superiority of mercap-toacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuro-protection studies. J. Med. Chem. 50:3054-3061.
80. Balasubramanian S, Verner E, Buggy JJ. (2009) Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett. 280:211-221.
81. Bertrand P. (2010) Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem. 45:2095-2116.
82. Bieliauskas AV, Pflum MK. (2008) Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 37:1402-1413.
83. Butler K V, Kozikowski A P. (2008) Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Des. 14:505-528.
84. Thomas EA. (2009) Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol. Neurobiol. 40:33-45.
85. Rivieccio MA, et al. (2009) HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc. Natl. Acad. Sci. U. S. A. 106:19599-19604.
86. Sandoval KE, Witt KA. (2008) Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol. Dis. 32:200-219.
87. Shapira Y, Setton D, Artru AA, Shohami E. (1993) Blood-brain barrier permeability, cerebral edema, and neurologic function after closed head injury in rats. Anesth. Analg. 77:141-148.
88. Witt KA, Mark KS, Sandoval KE, Davis TP. (2008) Reoxygenation stress on blood-brain barrier paracellular permeability and edema in the rat. Microvasc. Res. 75:91-96.
89. Morganti-Kossman MC, et al. (1997) Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol. Psychiatry. 2:133-136.
90. Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T. (2002) Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr. Opin. Crit. Care 8:101-105.
91. Scherbel U, et al. (1999) Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc. Natl. Acad. Sci. U. S. A. 96:8721-8726.